Trial Profile

Comparison of Biolimus-eluting Biodegradable Polymer, Everolimus-eluting and Sirolimus-eluting Coronary Stents.

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 10 Apr 2014

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Everolimus (Primary) ; Umirolimus (Primary)
Indications Coronary artery restenosis
Focus Therapeutic Use
Acronyms BESS

Most Recent Events

11 Feb 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
20 Jul 2012 According to ClinicalTrials.gov record, sirolimus-eluting stent treatment arm has been deleted. Now the trial consists of only 2 arms- biolimus-eluting and everolimus-eluting stent.
20 Jul 2012 Planned number of patients changed from 3000 to 1462 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com